Emerging Role of Sodium–Glucose Co-Transporter 2 Inhibitors for the Treatment of Chronic Kidney Disease
Rey Isidto,Romina Danguilan,Oscar Naidas,Russell Vilanueva,Mel-Hatra Arakama,Layla Marie Paraiso
DOI: https://doi.org/10.2147/IJNRD.S387262
2023-02-22
International Journal of Nephrology and Renovascular Disease
Abstract:Rey Isidto, 1 Romina Danguilan, 2 Oscar Naidas, 3 Russell Vilanueva, 2 Mel-Hatra Arakama, 2 Layla Marie Paraiso 2 1 HealthLink Medical, Surgical, Dental Clinics and Diagnostic Center, Iloilo City, Iloilo, Philippines; 2 Department of Adult Nephrology, National Kidney and Transplant Institute, Quezon City, Manila, Philippines; 3 Department of Adult Nephrology, St. Luke's Medical Center, Quezon City, Manila, Philippines Correspondence: Rey Isidto, HealthLink Medical, Surgical, Dental Clinics and Diagnostic Center, Iloilo City, Iloilo, Philippines, Tel +63 9178406232, Fax +63 33 3303863, Email Chronic kidney disease is one of the leading causes of morbidity and mortality in the Philippines. It is associated with a growing health burden as many patients progress to end-stage renal disease. Until recently, therapeutic options for the management of chronic kidney disease were limited. Sodium–glucose co-transporter 2 inhibitors offer an alternative therapeutic approach for patients with chronic kidney disease. Several trials have shown renal benefits with sodium–glucose co-transporter 2 inhibitors in patients with cardiovascular disease with and without type 2 diabetes and across a range of estimated glomerular filtration rate levels. In the Philippines, the sodium–glucose co-transporter 2 inhibitors dapagliflozin and canagliflozin are approved for the prevention of new and worsening nephropathy in type 2 diabetes. With emerging treatment options, an urgent need exists for guidance on the management of chronic kidney disease within the Philippines. In this review, we focus on the putative renal-protective mechanisms of sodium–glucose co-transporter 2 inhibitors, including effects on tubuloglomerular feedback, albuminuria, endothelial function, erythropoiesis, uric acid levels, renal oxygen demand, and hypoxia. Furthermore, we discuss the findings of recent large clinical trials using sodium–glucose co-transporter 2 inhibitors in patients with chronic kidney disease and diabetic kidney disease, summarize safety aspects, and outline the practical management of patients with chronic kidney disease in the Philippines. Keywords: chronic renal insufficiency, diabetic nephropathies, safety, sodium-glucose transporter 2 inhibitors Globally, chronic kidney disease (CKD) exerts a major patient and public burden, affecting almost 843.6 million individuals. 1,2 Angiotensin-converting enzyme (ACE) inhibitors and angiotensin II receptor blockers (ARBs) are the predominant pharmacological interventions available for the treatment of diabetic kidney disease (DKD) and non-DKD, albeit with limitations. 3,4 Concomitant treatment with an ACE inhibitor and ARB is associated with an increased risk of adverse events in patients with diabetic nephropathy. 5 A meta-analysis of 22 randomized controlled trials reported that both ACE inhibitors and ARBs increased the risk of developing hyperkalaemia in patients with CKD stages 3–5 with a glomerular filtration rate (GFR) of <60 mL/min per 1.73 m 2 and elevated serum creatinine levels. 4 Only 52–81% of the patients with CKD stages 3–5 receive renin–angiotensin system (RAS) blockers. 6 Despite available treatments, the global annual incidence of end-stage renal disease (ESRD) among patients with diabetes had increased from 375.8 to 1016.0 per million during 2000–2015, according to the latest published data. 7 During this period, the incidence of ESRD increased dramatically in Southeast Asia, and this region was reported as having the second highest incidence of ESRD globally. 7 Strict blood glucose with anti-diabetic therapies and blood pressure control by inhibition of angiotensin has been shown to be unable to stop disease progression to ESRD. 8,9 Therefore, new alternative treatment strategies are needed to effectively treat patients with CKD. Sodium–glucose co-transporter 2 (SGLT2) inhibitors have evolved from a novel hypoglycemic agent, to potent cardio- and renoprotective agent in type 2 diabetes (T2D), and recently, to an effective standalone therapeutic option for CKD regardless of the presence of diabetes mellitus (DM). 9 SGLT-2 is predominantly expressed in the proximal renal tubule, and accounts for 90% of renal glucose reabsorption. By inhibiting SGLT2, the glucose and sodium reabsorption is decreased, the tubule-glomerular feedback is restored and the aforementioned damage is undone. 10 Large-scale cardiovascular outcome trials investigating SGLT2 inhibitors have demonstrated that these therapies have renoprotective effects distinct from their glucose-lowering action, including the potential to reduce ESRD and acute kidney injury rates. 11,12 Recent studies conduc -Abstract Truncated-